Nektar Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. 

CEO
Howard W. Robin
CEOHoward W. Robin
Employees
61
Employees61
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
1990
Founded1990
Employees
61
Employees61

NKTR Key Statistics

Market cap
1.44B
Market cap1.44B
Price-Earnings ratio
-8.36
Price-Earnings ratio-8.36
Dividend yield
Dividend yield
Average volume
1.78M
Average volume1.78M
High today
$72.31
High today$72.31
Low today
$60.54
Low today$60.54
Open price
$63.32
Open price$63.32
Volume
4.79M
Volume4.79M
52 Week high
$72.31
52 Week high$72.31
52 Week low
$6.48
52 Week low$6.48

Stock Snapshot

With a market cap of 1.44B, Nektar Therapeutics(NKTR) trades at $69.97. The stock has a price-to-earnings ratio of -8.36.

On 2026-02-12, Nektar Therapeutics(NKTR) stock moved within a range of $60.54 to $72.31. With shares now at $69.97, the stock is trading +15.6% above its intraday low and -3.2% below the session's peak.

Trading volume for Nektar Therapeutics(NKTR) stock has reached 4.79M, versus its average volume of 1.78M.

Over the past 52 weeks, Nektar Therapeutics(NKTR) stock has traded between a high of $72.31 and a low of $6.48.

Over the past 52 weeks, Nektar Therapeutics(NKTR) stock has traded between a high of $72.31 and a low of $6.48.

NKTR News

Simply Wall St 13h
Nektar Therapeutics' Shares Climb 81% But Its Business Is Yet to Catch Up

Nektar Therapeutics ( ) shares have had a really impressive month, gaining 81% after a shaky period beforehand. This latest share price bounce rounds out a rema...

Nektar Therapeutics' Shares Climb 81% But Its Business Is Yet to Catch Up
TipRanks 2d
Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data

Nektar Therapeutics ( (NKTR) ) has shared an announcement. On February 10, 2025, Nektar Therapeutics reported positive 36-week blinded maintenance results from...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.